N-acetylcysteine prevented contrast-medium-induced nephropathy in primary angioplasty

November 2006
ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p63
Academic Journal
The article presents information on a study that was conducted to examine how N-acetylcysteine can prevent contrast-medium-induced nephropathy in primary angioplasty. About 354 patients, who received primary angioplasty for ST-elevation myocardial infarction within 12 hours after onset of symptoms, were taken as subjects. In patients having primary angioplasty, N-acetylcysteine was said to reduce the incidence of contrast-medium-induced nephropathy.


Related Articles

  • Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Mechanical Intervention for Acute Myocardial Infarction. Antoniucci, David // Current Medicinal Chemistry - Cardiovascular & Hematological Age;Jul2005, Vol. 3 Issue 3, p173 

    Limitations in study designs and adoption of rigid criteria for randomization in clinical trials on acute myocardial infarction (AMI) may result in the enrolment of artificial populations, and subsequent trial results may be misleading in many ways rendering problematic the generalization of the...

  • Coronary Artery Disease -- Myocardial Infarction.  // Current Medical Literature: Interventional Cardiology Monitor;2005, Vol. 12 Issue 4, p99 

    The article presents information about several papers related to myocardial infarction, a coronary artery disease. The article titled "Relation of interhospital delay and mortality in patients with ST-segment elevation myocardial infarction transferred for primary coronary angioplasty,"...

  • Efficacy of Coronary Angioplasty on Long-Term Outcome in Elderly Chinese Patients with ST Elevated Myocardial Infarction. JieYan Shen; YongPing Du; Wei Song; JianPing Liu; ShuXuan Jin; Jun Bu; Ben He // Cell Biochemistry & Biophysics;Jul2010, Vol. 57 Issue 2/3, p59 

    The benefit and efficacy of interventional coronary therapies in elderly patients is still a controversial subject, especially in parts of the world where traditional and conservative medicine is still mainstream. In China, the benefit of intervention is still questionable, hence, this study...

  • SHOULD ALL PATIENTS WITH AN ACUTE MYOCARDIAL INFARCTION BE REFERRED FOR DIRECT PTCA? de Joegere, Peter P.; Serruys, Patrick W.; Simoons, Maarten L. // Heart;Nov2004, Vol. 90 Issue 11, p1352 

    The article focuses on the treatment of acute myocardial infarction (AMI) by percutaneous transluminal coronary angioplasty (PTCA). Acute myocardial infarction (AMI) is a frequent clinical condition associated with a high immediate and short term mortality and long term morbidity. The...

  • Five-Year Prognosis in an Incident Cohort of People Presenting with Acute Myocardial Infarction. Simpson, ,4Colin R.; Buckley, Brian S.; McLernon, David J.; Sheikh, Aziz; Murphy, Andrew; Hannaford, Philip C. // PLoS ONE;2011, Vol. 6 Issue 10, p1 

    Background: Following an AMI, it is important for patients and their physicians to appreciate the subsequent risk of death, and the potential benefits of invasive cardiac procedures and secondary preventive therapy. Studies, to-date, have focused largely on high-risk populations. We wished to...

  • Adjunctive streptokinase offers no benefit to PTCA for acute MI.  // Geriatrics;Jun1993, Vol. 48 Issue 6, p75 

    The article reports that patients who undergo percutaneous transluminal coronary angioplasty (PTCA) for acute myocardial infarction (MI) derive no extra benefit from the routine adjunctive use of IV streptokinase, The finding was reported by the authors of a small, prospective,...

  • Adjunctive treatment with eplerenone reduced 30-day all-cause mortality in acute myocardial infarction.  // ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p15 

    This article focuses on a study conducted to examine the efficacy of eplerenone in reducing 30-day all-cause mortality in acute myocardial infarction (MI). Randomized placebo-controlled trial was conducted on 6632 patients with acute MI complicated by left-ventricular systolic dysfunction and...

  • Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial.  // Current Medical Literature: Cardiology;2010, Vol. 29 Issue 4, p123 

    The article assesses the potential of non-culprit coronary artery percutaneous coronary intervention (PCI) in treating ST-segment elevation myocardial infarction (STEMI), as shown in a published study in the 2010 edition of "European Heart Journal." The study was done on 5,745 patients separated...

  • Clopidogrel "highly cost effective" after PCI in the US.  // PharmacoEconomics & Outcomes News;9/24/2005, Issue 487, p7 

    Discusses research being done on the effectiveness of clopidogrel therapy in the U.S. for the prevention of cardiovascular-related morbidity and mortality in patients who have experienced a myocardial infarction and who undergo percutaneous coronary intervention. Reference to a study conducted...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics